Loading...
Market
Will a clinical trial confirm Ozempic's Alzheimer's risk reduction by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Peer-reviewed medical journals and clinical trial registries
Story
Study Finds Ozempic Cuts Alzheimer's Risk by 70% in Type 2 Diabetes
Oct 24, 2024, 11:11 AM
An observational study analyzing medical records has found that semaglutide, the active ingredient in diabetes medications like Ozempic and Wegovy developed by Novo Nordisk, may significantly reduce the risk of Alzheimer's disease in people with type 2 diabetes. The study, published Thursday, showed that patients taking Ozempic had a 70% lower risk of being diagnosed with Alzheimer's compared to those taking other diabetes drugs. This finding suggests potential benefits of semaglutide in neurodegenerative diseases beyond its established use in managing diabetes and aiding weight loss.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Below 40% • 25%
40% - 50% • 25%
50% - 60% • 25%
Above 60% • 25%
Yes • 50%
No • 50%
0 countries • 25%
1-5 countries • 25%
6-10 countries • 25%
More than 10 countries • 25%
